Shares of drugmaker Sanofi (NYSE:SNY) failed to keep up with the broader market in 2013, and the stock is down nearly 8% year to date. Disappointing guidance and the recent FDA rejection of multiple sclerosis treatment Lemtrada have driven shares down. However, is the market being myopic? Could Sanofi be positioned for growth, and are its shares valued attractively compared to its Big Pharma peers? Analysts Max Macaluso and David Williamson discuss this dividend stock in the following video.
More rock solid dividend stocks investors need to know
One of the dirty secrets that few finance professionals will openly admit is the fact that dividend stocks as a group handily outperform their non-dividend paying brethren. The reasons for this are too numerous to list here, but you can rest assured that it's true. However, knowing this is only half the battle. The other half is identifying which dividend stocks in particular are the best. With this in mind, our top analysts put together a free list of nine high-yielding stocks that should be in every income investor's portfolio. To learn the identity of these stocks instantly and for free, all you have to do is click here now.
David Williamson has no position in any stocks mentioned. Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool recommends Alnylam Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.